摘要
目的:以微血管密度(micro vessel density,MVD)为标记,探讨Bcl-2和Bax在非小细胞肺癌(non-small cell lung cancer,NSCLC)组织和正常肺组织中的不同表达,及在肺癌发生、转移及预后中的不同表达。方法:采用免疫组织化学的方法(SP法),检测63例NSCLC标本中Bcl-2和Bax蛋白与21例正常肺部组织的细胞表达之间的差异,并测定MVD。结果:Bcl-2和Bax之间具有较强的负相关性。Bcl-2、Bax表达的阳性率与NSCLC组织分化程度、TNM分期存在显著性差异(P<0.05),但与性别及生存期限无关。MVD和分化程度、TNM临床分期及淋巴结是否转移、生存期限有显著性关系,但和吸烟及性别无关,和组织学类型无显著性关系。结论:MVD在癌症早期随Bcl-2和Bax一起呈高表达,但随着肿瘤细胞的扩散,Bcl-2就失去了调控的作用,即出现基因表达的"钝化"现象。这提供了一条针对早期肺癌MVD升高的Bcl-2/Bax分子靶向治疗方法。
Objective:To explore the expressions difference of Bcl-2 and Bax factors in non-small cell lung cancer(NSCLC) and normal lung tissues by means of micro vessel density(MVD) symbol.Trace the two factors different expression during carcinogenesis and progression of lung cancer.Methods: To explore expressions difference of Bcl-2 and Bax in 63 cases with pathologically diagnosed NSCLC and 31 cases with normal lung tissues.Immunohistochemical technique and MVD count were employed.Results: Negative correlations were observed between Bcl-2 and Bax.The positive rate of Bcl-2 and Bax expression were significant in the high,middle and low differentiation of NSCLC,and so be the TNM staging of lung cancer Bcl-2(P〈0.05),but insignificant in gender and survival period.The positive rate of MVD were significant in the high,middle and low differentiation of NSCLC,and so be the TNM staging of lung cancer(P〈0.05),but insignificant in gender,smoking experience and tissues type.Conclusion: MVD has higher expression with Bcl-2 and Bax at early stage.But Bcl-2 will be passivated as cancer tissues diffusion.The method shows a new molecular targeted therapy with Bcl-2/Bax molecule for lung cancer at early stage.
出处
《海南医学院学报》
CAS
2009年第10期1208-1211,共4页
Journal of Hainan Medical University
基金
海南医学院科研基金资助学报项目(0020090181)~~